|
|
RANITIDIN
-
| StockNo |
Product description |
| EB0280-442-06 |
RANITIDIN
FILMTABL 150 MG X 60 |
-
- COMPOSITION:
Ranitidin hydrochloride, equivalent to Ranitidin 150 mg in one
filmtablet.
ACTION:
Ranitidin is a highly effective, fast acting blocker of histamine
H2- receptors in the stomach. It inhibits the basal and stimulated
secretion of hydrochloride acid; reduces the quantity of the
secreted gastric juice and its qualitative composition (both the
pepsin and the acid content is reduced). Ranitidin has a
long-lasting action: the single dose suppresses the gastric acid
secretion for about 12 h.
PHARMACOKINETICS:
Ranitidin absorption after oral intake is fast and is not affected
by food or antacids. Maximum plasma concentrations are attained 2 h
after intake. Half-elimination time is almost 2 h. its plasma
half-life is 3-4 h. It crosses the blood-brain and the placental
barrier. Excreted through the kidneys, mainly unchanged and
partially as metabolites.
INDICATIONS:
Gastric ulcer (primary and post-resection), Zollimger-Ellison
syndrome, duodenal ulcer, reflux esophagitis; prophylaxis of
recurrences of gastric and duodenal ulcer.
CONTRAINDICATIONS:
During pregnancy and breast-feeding, it can be administered only
after strictly specified indications. Do not administer to children
below 8 years of age.
SIDE EFFECTS:
It has no effect on the endocrine gonadotropic function, but its
administration to little girls should be under strict observation.
It rarely induces headache, rashes, dizziness, nausea and diarrhea,
which do not necessitate the discontinuation of the treatment.
Elevated transaminase level is likely to occur. |
PRECAUTIONS:
The treatment is initiated only after accurate diagnosis: in the
presence of a malignant tumor, the clinical picture may be masked
and changed.
DRUG INTERACTIONS:
The elimination of oral anticoagulants, benzodiazepins,
betablockers, theophyllin and novocain is suppressed in case of
simultaneous administration; Ranitidin inhibits the absorption of
antacids containing aluminum and magnesium, and of ketoconazol.
DOSAGE AND ADMINISTRATION:
The usual schedule for adults - 1 tablet, 2 times daily (morning and
evening), regardless of the time of the meals, or 2 tablets in the
evening before going to bed. The therapeutic course lasts from 4 to
8 weeks, as the effect occurs after about 4 weeks. Prophylactic and
maintenance dose - 1 tablet in the evening before bedtime.
In reflux esophagitis - the initial dose is 1 tablet, 3 times daily.
For children from 8 to 16 years - 1 tablet, 2 times daily.
In severe renal insufficiency, the daily dose is reduced to 1 tablet
in the evening, for a course of also 4 to 8 weeks. It can be
administered to patients with a transplanted kidney.
MEDICINAL FORM AND PACKAGE:
Packages with 60 filmtablets of 150 mg.
STORAGE:
At moderate temperature (15-30° C), in a place protected from
moisture and direct sunlight.
EXPIRY:
2 (two) years.
|
|
|
